Elagolix (NBI-56418)

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
1 mg	3-5days	$100.00	Visible after login	- +
5 mg	3-5days	$215.00	Visible after login	- +
10 mg	3-5days	$338.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

1 mg

3-5days

$100.00

Visible after login

- +

5 mg

3-5days

$215.00

Visible after login

- +

10 mg

3-5days

$338.00

Visible after login

- +

Product Overview

Product Name	Elagolix (NBI-56418)
CAS	834153-87-6
Formula	C32H30F5N3O5
MW	631.59
Appearance	White to off-white powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

Elagolix (formerly NBI56418; ABT620; NBI-56418; ABT-620; trade name: Orilissa) is a potent, specific, orally bioavailable, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) used for pain management. It inhibits GnRHR with a Kd of 54 pM. Elagolix was given FDA approval on July 23, 2018, to treat endometriosis-related moderate to severe pain. A short-acting GnRH antagonist, elagolix suppresses ovarian estrogen production in a dose-dependent manner, resulting in partial suppression at lower doses and complete suppression at higher doses. Because Elagolix is non-peptide and readily absorbed through the mouth, it is considered the leader of a new class of GnRH inhibitors known as second-generation inhibitors.

Related literature

Sorry, there is no relevant literature

Sorry, no related items

History